Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. The SGLT-2 inhibitors are increasingly recognized as transformative agents in the DN market, with growing clinical adoption. The use of Bayer’s finerenone (Kerendia), first and only MRA approved by the FDA for DN, is expanding. The role of GLP-1 RA products, such as semaglutide and tirzepatide, is also growing progressively for DN. This report provides important insights into how these agents are used in the management of diabetic nephropathy and how practices are evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DN patients?
- How have SGLT-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of DN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DN patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Boehringer Ingelheim, AstraZeneca, Bayer, Johnson & Johnson innovative medicine, Amgen, Novo Nordisk, Eli Lilly
Key drugs: RAAS inhibitors, beta blockers, CCBs, MRAs, insulins, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 RA products
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product enhancement
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
